Ecole Polytechnique Federale De Lausanne

Centre Hospitalier Universitaire Vaudois (c.h.u.v.)

Centre Hospitaller Universitaire Vaudois (chuv)

Patrice Jichlinski

Hubert Van Den Bergh

Georges Wagnieres

Norbert Lange

Matthieu Zellweger

Pavel Kucera

Denise Nardelli Haefliger

Sonia Domingos Pereira

Alexandre Marti

The present invention relates to a pharmaceutical composition comprising a live attenuated non-recombinant mutant ofserovarstrain and/or a non-viable attenuated non-recombinant mutant ofserovarstrain for use the treatment of cancer recurrence/progression. Preferably the cancer is bladder cancer.

[object Object]

The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.

Solution for diagnosing or treating tissue pathologies

Growing community of inventors

Le Mont-sur-Lausanne, Switzerland

Patrice Jichlinski